KCT0005683招募中未知
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy
Pfizer Pharmacueticals Korea0 个研究点目标入组 99 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 4(Year) 至 7(Year)（—）
- 性别
- Male
入选标准
- •1. Male participants who are =4 and <8 years of age at Screening (Visit 1).
- •2. Confirmed diagnosis of DMD by prior genetic testing demonstrating the presence of a mutation in the dystrophin gene consistent with DMD at Screening (Visit 1). If the Investigator determines that the results are inconclusive, a repeat genetic testing will be allowed through the central laboratory at Screening (Visit 1).
- •3. Receipt of a stable daily dose of glucocorticoids (=0.5 mg/kg/day prednisone,prednisolone, or =0.75 mg/kg/day deflazacort) for at least 3 months prior to Screening (Visit 1) and during the period between Screening (Visit 1) and Day 1 (Visit 3). In
- •order to comply with protocol procedures, there should also be a reasonable expectation that this daily dose of glucocorticoids will remain stable for the first 2 years of the study. A stable dose is defined as one in which any change is =0.2 mg/kg
- •4. A NSAA total score >16 and <30 at Screening (Visit 1).
- •5. Ambulatory, defined as being able to walk 10 meters unassisted, at Screening (Visit 1).
- •6. Participants/legally acceptable representatives who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures including, potentially, open and/or needle muscle biopsies under general anesthesia.
- •7. Participants/legally acceptable representatives who are capable of giving assent/signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the assent/informed consent document (ICD) and in this protocol.
- •8. Participants/legally acceptable representatives who are willing to protect the integrity of the study data by not actively seeking sensitive clinical data (eg, CK, ALT, AST, NAb to AAV9) through independent laboratory tests and by not sharing trial
- •experiences with other participants or publicly (eg, through social media).
排除标准
- •1. Prior treatment with gene therapy, defined as any therapy introducing exogenous DNA or intended to permanently alter the endogenous DNA. Gene therapy (other than IP) will be prohibited for the duration of the study.
- •2. Exposure within 6 months prior to Screening (Visit 1) to any treatment designed to increase dystrophin expression (including, but not limited to exon-skipping and nonsense read-through). These treatments will also be prohibited during the period
- •between Screening (Visit 1) and Day 1 (Visit 3) and for the first 2 years of the study.
- •3. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) at Screening (Visit 1). These treatments will also be prohibited during the period between Screening (Visit 1) and Day 1 (Visit 3) and for the first 2 years of the study.
- •4. Known cognitive impairment or behavioral issues that would impede the ability to follow instructions, in the judgment of the Investigator, at Screening (Visit 1).
- •5. Any nonhealed injury at Screening (Visit 1) which, in the opinion of the Investigator, may impact functional testing; additionally, lower limb fractures must have been healed for at least 3 months prior to Screening (Visit 1).
- •6. Positive test for NAb to AAV9, based on the threshold determined by the Central Laboratory, from a sample taken at Screening (Visit 1).
- •7. Receipt of a live attenuated vaccination within 90 days prior to Screening (Visit 1). Receipt of a live attenuated vaccination will also be prohibited during the period between Screening (Visit 1) and Day 1 (Visit 3), for 90 days prior to Year 2 IP
- •administration, and for the first 2 months after each IP administration.
- •8. Receipt of an influenza vaccination, systemic antiviral and/or interferon therapy within 30 days prior to Screening (Visit 1). Receipt of an influenza vaccination, systemic antiviral and/or interferon therapy will also be prohibited during the period
- •between Screening (Visit 1) and Day 1 (Visit 3), for 30 days prior to Year 2 IP administration, and for the first 2 months after each IP administration.
- •9. Receipt of any systemic immunosuppressant agents other than glucocorticoids within 30 days prior to Screening (Visit 1). Receipt of any systemic immunosuppressant agents other than glucocorticoids will also be prohibited during the period between Screening (Visit 1) and Day 1 (Visit 3) and during the first 2 years of the study, unless administered in response to immunologic reaction.
- •10. Abnormality in hematology or chemistry profiles at Screening (Visit 1). A single repeat for value(s) outside allowable limits is permitted to re-assess eligibility:
- •a. Absolute neutrophil count <1000 cells/mm3;
- •b. Cystatin C >1.0 mg/L;
- •c. Positive hepatitis A virus (anti-HAV) immunoglobulin M, hepatitis B surface antigen (HBsAg), and/or
- •hepatitis C antibody (HCVAb);
- •d. Markers of hepatic inflammation or overt or occult cirrhosis as evidenced by one or more of the following:
- •1. Prothrombin time (PT) > upper limit of normal (ULN); prolonged international normalized ratio (INR) >ULN;
- •2. GLDH >2 x ULN;
- •3. Total bilirubin >1.5 x ULN(unless the participant has a history of Gilbert disease) and direct bilirubin >0.5 mg/dL;
- •4. Gamma-glutamyl transferase (GGT) >1.5 x ULN.
- •11. Other acute or chronic medical or psychiatric condition at Screening (Visit 1), including recent
研究者
相似试验
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-001339-38-PLOtsuka Pharmaceutical Development & Commercialization, Inc.550
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-001339-38-CZOtsuka Pharmaceutical Development and Commercialization, Inc.550
进行中（未招募）
1 期
Phase 3 study to evaluate safety and effectiveness of oral Apremilast(CC-10004) in patients with Psoriatic ArthritisPsoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.MedDRA version: 14.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2010-018386-32-HUCelgene Corporation495
招募中
1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)MedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849Atrial FibrillationCTIS2023-503224-66-00Anthos Therapeutics Inc.1,963
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus valganciclovir is in treating cytomegalovirus in hematopoietic stem cell transplant patients.EUCTR2015-004726-34-ITSHIRE HUMAN GENETIC THERAPIES, INC550